Yet another clinical trial has gone well for an Alnylam drug candidate, the company announced Tuesday. The tested compound, lumasiran, is intended to treat a rare genetic liver disease that can lead to serious kidney damage known as primary hyperoxaluria type 1, or PH1.
Alnylam expects to file for approval in the U.S. and Europe early next year, according to the company’s press release. Based on trademark filings, the drug may be branded as Oxlumo; the company would not confirm or deny the drug’s name.
Lumasiran could become the company’s third approved drug in as many years, achieving a goal Alnylam set for itself in 2015.